Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(1)
Other(3)

Detailed Status

Suspended3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

suspended375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
suspendedphase_1

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

NCT00673829
terminatedphase_1

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

NCT00673322
suspendedphase_1

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

NCT00664196
suspendedphase_2

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

NCT01723306

Clinical Trials (4)

Showing 4 of 4 trials
NCT00673829Phase 1

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

Suspended
NCT00673322Phase 1

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Terminated
NCT00664196Phase 1

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Suspended
NCT01723306Phase 2

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Suspended

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4